Prescription drug · ANDA
Cabergoline NDC 69238-2693
Cabergoline .5 mg/1 · Tablet · Oral · Amneal Pharmaceuticals NY LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 69238-2693-1 | 69238269301 | 8 TABLET in 1 BOTTLE (69238-2693-1)Marketed from Oct 3, 2024 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Cabergoline
- Generic name (nonproprietary)
- cabergoline
- Active ingredients
- Cabergoline — .5 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 218618
- Marketing start
- Listing expires
- Other FDA classes
- Ergolines (Chemical structure)
- Identifiers
- Product ID 69238-2693_3e2ff3e8-fa09-469e-b545-68ab6b168de7SPL ID 3e2ff3e8-fa09-469e-b545-68ab6b168de7SPL set ID a246b015-e19c-4b4f-9089-aea1108687baRxCUI 199703UNII LL60K9J05TUPC 0369238269314
- Pharmacologic class
- Ergot Derivative
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N469238269301followed by a unit qualifier and the quantityPackage 69238-2693-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas.
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 218618
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Cabergoline | Cabergoline .5 mg/1 | TabletOral | A-S Medication Solutions | 50090-7642 |